The purpose of this study is to evaluate whether a drug called dapagliflozin is safe and effective when added to conventional heart failure therapy in patients who have been admitted to the hospital for acute heart failure. Participants will be randomly assigned to receive either dapagliflozin or placebo (inactive substance). In addition, they be asked about their medical history and medications, as well as their health and quality of life. Blood samples will also be taken to check creatinine and potassium levels.
Dapagliflozin has been approved by the U.S. Food and Drug Administration (FDA) for various conditions, but its use in this study is investigational.
What is the full name of this clinical trial?
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68